Tools to implement measurement-based care (MBC) in the treatment of opioid use disorder (OUD): toward a consensus.

"Declarations Ethics approval and consent to participateNot applicable. Consent for publicationNot applicable. Competing interestsA. John Rush has received consulting fees from Compass Inc., Curbstone Consultant LLC, Emmes Company, Evecxia Therapeutics, Inc., Holmusk Technologies, Inc., ICON, PLC, Johnson and Johnson (Janssen), Liva-Nova, MindStreet, Inc., Neurocrine Biosciences Inc., Otsuka-US; speaking fees from Liva-Nova, Johnson and Johnson (Janssen); and royalties from Wolters Kluwer Health, Guilford Press and the University of Texas Southwestern Medical Center, Dallas, TX (for the Inventory of Depressive Symptoms and its derivatives). He is also named co-inventor on two patents: U.S. Patent No. 7795033: Methods to Predict the Outcome of Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S, Wilson AS; and U.S. Patent No. 7906283: Methods to Identify Patients at Risk of Developing Adverse Events During Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S. Robert E. Gore-Langton receives salary from the Emmes Company for work performed on a contract with the National Institute on Drug Abuse (NIDA). Gavin Bart has received honoraria from the American Academy of Addiction Psychiatry for participating in the SAMHSA-funded Providers Clinical Support System-Exchange. He has also received payment from the University of Missouri to provide content expertise to a US State Department-funded international addiction workforce capacity building effort. Katharine Bradley led the technical panel and co-authored the Short Drug Monitor measure. Cynthia Campbell has received support managed through her institution from the Industry PMR Consortium, a consortium of companies working together to conduct post marketing studies required by the Food and Drug Administration that assesses risks related to opioid analgesic use. James McKay has received royalties from UpToDate, Inc. David W. Oslin has received grant funding from Janssen Pharmaceuticals and Myriad Genetics. Andrew J. Saxon has received travel support from Alkermes, Inc., honorarium from Indivior, Inc., and royalties from UpToDate, Inc. T. John Winhusen has no conflicts of interest. Li-Tzy Wu has no conflicts of interest. Betty Tai has no disclosures. Landhing M. Moran has no disclosures. Competing interests A. John Rush has received consulting fees from Compass Inc., Curbstone Consultant LLC, Emmes Company, Evecxia Therapeutics, Inc., Holmusk Technologies, Inc., ICON, PLC, Johnson and Johnson (Janssen), Liva-Nova, MindStreet, Inc., Neurocrine Biosciences Inc., Otsuka-US; speaking fees from Liva-Nova, Johnson and Johnson (Janssen); and royalties from Wolters Kluwer Health, Guilford Press and the University of Texas Southwestern Medical Center, Dallas, TX (for the Inventory of Depressive Symptoms and its derivatives). He is also named co-inventor on two patents: U.S. Patent No. 7795033: Methods to Predict the Outcome of Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S, Wilson AS; and U.S. Patent No. 7906283: Methods to Identify Patients at Risk of Developing Adverse Events During Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S. Robert E. Gore-Langton receives salary from the Emmes Company for work performed on a contract with the National Institute on Drug Abuse (NIDA). Gavin Bart has received honoraria from the American Academy of Addiction Psychiatry for participating in the SAMHSA-funded Providers Clinical Support System-Exchange. He has also received payment from the University of Missouri to provide content expertise to a US State Department-funded international addiction workforce capacity building effort. Katharine Bradley led the technical panel and co-authored the Short Drug Monitor measure. Cynthia Campbell has received support managed through her institution from the Industry PMR Consortium, a consortium of companies working together to conduct post marketing studies required by the Food and Drug Administration that assesses risks related to opioid analgesic use. James McKay has received royalties from UpToDate, Inc. David W. Oslin has received grant funding from Janssen Pharmaceuticals and Myriad Genetics. Andrew J. Saxon has received travel support from Alkermes, Inc., honorarium from Indivior, Inc., and royalties from UpToDate, Inc. T. John Winhusen has no conflicts of interest. Li-Tzy Wu has no conflicts of interest. Betty Tai has no disclosures. Landhing M. Moran has no disclosures."

"Funding This workgroup was supported by the National Institute on Drug Abuse (NIDA), Center for the Clinical Trials Network (CCTN). REGL was supported by contracts 75N9501900013 and 7595022D00017 to Emmes."